Challenging behaviour and sleep cycle disorder following brain injury: A preliminary response to agomelatine treatment

B. O'Neill, M. Gardani*, G. Findlay, T. Whyte, T. Cullen

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Sleep disturbances are common after acquired brain injury. Sedatives can exacerbate behavioural disorders. 

Objectives: This study reports the case of a severely brain damaged man (TM) who developed a non-24 hour sleep cycle disorder that was effectively managed by the administration of a melatonin receptor agonist, agomelatine. 

Method: TM suffered significant brain damage as a result of a large subarachnoid haemorrhage of his right anterior cerebral artery complicated by midline shift and subsequent infarction of his left middle cerebral artery. In addition to challenging behaviour and cognitive impairment, TM presented with a recurrent disturbed sleep-wake pattern that significantly worsened his quality-of-life. He was diagnosed as suffering of non-24 hour sleep-wake disorder. Challenge was recorded using the Overt Aggression Scale Modified for Neuro-Rehabilitation (OASMNR). 

Results: Typical hypnotics had no or ill effects. Agomelatine prescription (25 mg) led to significant OASMNR and sleep efficiency change with effects apparent at 1.5 years later. 

Conclusions: Administration of the melatonin receptor (MT1 and MT2) agonist agomelatine each night resulted in an immediate and sustained improvement on sleep and on indices of challenging behaviour.

Original languageEnglish
Pages (from-to)378-381
Number of pages4
JournalBrain Injury
Volume28
Issue number3
Early online date30 Dec 2013
DOIs
Publication statusPublished - Mar 2014

Keywords / Materials (for Non-textual outputs)

  • behavioural disorder
  • endocrinology
  • sleep disorder
  • subarachnoid haemorrhage

Fingerprint

Dive into the research topics of 'Challenging behaviour and sleep cycle disorder following brain injury: A preliminary response to agomelatine treatment'. Together they form a unique fingerprint.

Cite this